Research Article| Volume 30, ISSUE 10, P1934-1936, October 2008

The author responds

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lucasti C
        • Jasovich A
        • Umeh O
        • et al.
        Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
        Clin Ther. 2008; 30: 868-883
      1. Merrem IV (Meropenem) [package insert]. AstraZeneca, Wilmington, DE2007
        • Jaruratanasirikul S
        • Sriwiriyajan S
        Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
        J Antimicrob Chemother. 2003; 52: 518-521
        • Sun HK
        • Kuti JL
        • Nicolau DP
        Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: A report from the OPTAMA program.
        Crit Care Med. 2005; 33: 2222-2227
        • Chastre J
        • Wunderink R
        • Prokocimer P
        • et al.
        Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study.
        Crit Care Med. 2008; 36: 1089-1096
      2. Primaxin IV (imipenem/cilastatin) [package insert]. Merck, Whitehouse Station, NJ2007